HOME >> MEDICINE >> NEWS
New rheumatoid arthritis drug developed at UCSD promises improved treatment options

Researchers at the University of California, San Diego (UCSD) School of Medicine have announced successful completion of Phase II clinical trials of a novel drug for the treatment of rheumatoid arthritis (RA), one that works without suppressing the patient's immune system.

Salvatore Albani, M.D., Ph.D, professor of medicine and pediatrics and Director of the Translational Research Unit of the Clinical Investigation Institute (CII) at the UCSD School of Medicine, recently presented a summary of the findings at the "Frontiers of Clinical Investigation Symposium." The symposium, sponsored by the CII and Nature Medicine, was held in La Jolla, California in September.

The new drug, dnaJP1, is a peptide derived from a naturally occurring protein, dnaJ, which generates inflammation in RA patients, whose inflammatory-control mechanisms are impaired. The impairment causes the body's T cells which trigger inflammation to kill and clear foreign pathogens in the body to attack the body's own tissues.

"In essence, we re-educated the immune system T cells to be tolerant of the dnaJP1 amino acid sequence, which would usually contribute to inflammation in rheumatoid arthritis patients," Albani said.

DnaJP1 works by resetting the ability of the patient's immune system to tolerate dnaJ, thus transforming a potentially damaging trigger into a tool for controlling the disease. Oral ingestion of dnaJP1 is key, because the mucosal immune system found in the gut has the ability to "teach" the body to view a protein as one that isn't dangerous or foreign. Much as food is ingested into the body and not rejected, the body tolerates dnaJP1.

Current medications for treating RA range from anti-inflammatory drugs, such as aspirin, to corticosteroids and medicines that alleviate symptoms by suppressing or killing the body's immune response, basically crippling the body's ability to defend itself against other infectious diseases or cancer.


'"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
14-Oct-2005


Page: 1 2 3

Related medicine news :

1. Green tea compound may be a therapy for people with rheumatoid arthritis
2. The link between rheumatoid arthritis and cancer
3. Predicting the risk of rheumatoid arthritis for early arthritis patients
4. Women with rheumatoid arthritis have significantly less chance of remission than men
5. New study reveals postcode lottery for rheumatoid arthritis treatment
6. Cancer drug may be remedy for rheumatoid arthritis, Stanford study finds
7. A new approach to rheumatoid arthritis
8. Increased odds of rheumatoid arthritis in women smokers without genetic risk factor
9. New research addresses taboos around the impact of rheumatoid arthritis on patients sex lives
10. New evidence shows MabThera inhibits joint damage in patients with rheumatoid arthritis
11. PTPN22 gene associated with both susceptibility and disease progression in rheumatoid arthritis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... June 28, 2017 , ... ... servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with the ... for families with children receiving treatment in nearby hospitals. , Ronald McDonald House ...
(Date:6/27/2017)... ... June 27, 2017 , ... Harbour , a DAO (decentralized ... the Ethereum blockchain, has released their technical specifications . , 2017 has seen ... little systematic approach for determining which offerings will garner the greatest ROI. Dean Eigenmann, ...
(Date:6/27/2017)... NY (PRWEB) , ... June 27, 2017 , ... From ... members. The three-day event was held in Syracuse, New York, where EarQ is headquartered. ... changing industry, how to connect with today’s savvy consumer, and the latest in ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR News is looking for ... guidebook. This guidebook offers an excellent branding and exposure opportunity for the author ... and how-to’s that fall into the following categories:, ,     Media ...
(Date:6/27/2017)... ... June 27, 2017 , ... Hammer Strength, the world’s leading performance ... Javair Gillett of the Houston Rockets the NBSCA Strength & Conditioning Coach of the ... by NBSCA members who vote to select the coach who embodies the highest level ...
Breaking Medicine News(10 mins):
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/24/2017)... , May 24, 2017  ivWatch LLC ... Equipment Manufacturer (OEM) Board to enable seamless integration ... patient monitoring systems, infusion pumps and other devices. ... will be able to help health care customers ... reduced risks related to IV therapy. ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology:
Cached News: